Douglas
About
News
Careers
Products
Partnerships
Get in touch
DouglasNEW ZEALAND.COM Licence No.101032
  • About
  • Leadership team
  • Operations
  • Corporate social responsibility
  • Terms and conditions of supply
  • Supplier code of conduct
  • Follow us on LinkedIn
  • Careers
  • Vacancies
  • Teams at Douglas
  • Partner with us
  • In-licensing
  • Out-licensing
  • Co-development
  • Drug repurposing
  • Brand representation
  • CDMO

All rights reserved © 2026 Douglas Limited

  • Privacy Policy
  3. Partner with Us
  5. Drug repurposing
  2. Partner with Us

Drug repurposing

Douglas softgels

Drug repurposing pipeline

At Douglas Pharmaceuticals, we breathe new life into established molecules by uncovering novel therapeutic indications.

We are actively seeking strategic collaborators, clinical researchers, and biopharma partners to co-develop and accelerate these high-potential drug repurposing assets toward global commercialisation.

If you are interested in unlocking the hidden potential of proven therapies and expanding patient access together, we invite you to explore our current pipeline opportunities and connect with our alliance management team.

R-107 no partner
Major depressive disorder / TRD

R-107

R-107 is the first and only oral extended-release ketamine tablet transforming Treatment Resistant Depression and other depressive disorders.

R-107 is in a special purpose vehicle, Tasman Therapeutics, which is actively seeking strategic partners and investors.

Learn more about R-107
R-131-2 no partner
HPV and related cervical dysplasia

R-131-2

R-131-2 is a novel soft gel vaginal insert which is being developed to treat HPV related cervical diseases.

Douglas has partnered with Daré Bioscience to take this development into Phase 2 clinical trials for the US market. We are actively seeking partners in the EU/ROW markets.

Daré Bioscience announcement of FDA Clearance of IND for Phase 2
R-178
Inflammatory bowel disease

R-178 and R-209

R-178 and R-209 are novel Thioguanine dosage forms to treat inflammatory bowel disease.

Contact us for more information
R-192
Major depressive disorder

R-192

R-192 is the second generation of the R-107 project, based on an analogue of Ketamine.

Contact us for more information
DML Warehouse
DML production
Contact us

Ready to partner with Douglas?

Contact us